NCT01331603|Unknown
Loading search results
Sponsor study identifier
observational
50
1 country
1
Study Start
March 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Recently, it has been demonstrated that iron overload is associated with the appearance of labile plasma iron (LPI). LPI is redox active and is rapidly taken up by cells, leading to a rise in the labile iron pool (LIP) and catalyzing generation of reactive oxygen species (ROS), which can lead to cellular damage. The LPI data are mostly derived from thalassemia iron overload research , however, there are a few data describing LPI and its correlations with the classical iron overload parameters (ferritin, TSAT) in acute anemias such as MDS Therefore we are going to assess LPI in iron overloaded myelodysplastic syndromes (MDS) (low and high risk) and primary myelofibrosis, in order to assess whether it can be used as alternative to the routinely used parameters; TSAT and ferritin levels.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 18, 2011
Actual (reported)March 2011
Date type not reportedThis date has not been verified as actual or estimated.
April 8, 2011
Actual (reported)January 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The value of Ferritin,Transferrin Saturation,CRP and LPI at the blood samples
The blood samples should be taken at least one week apart from last blood transfusion. In case of infection or acute inflammation , blood samples should be taken only one week after resolution of these conditions.
1 year
patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
low and high risk MDS patients and primary myelofibrosis patients.The risk stratification of these patients will be calculated according to the WPSS (WHO adapted Prognostic Scoring System)
Wolfson Medical Center
Holon, Israel
Ghoti Hussam, MD
Hematolgy Department of Wolfson Medical Center
First Submitted
January 18, 2011
First Posted
April 8, 2011
Study Start
March 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2013
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2013
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 8, 2011
Record last verified: 2011-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: